- Home
- AGIO vs HE Comparison
AGIO vs HE Comparison
Compare AGIO & HE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- HE
- Stock Information
- Founded
- AGIO 2007
- HE 1891
- Country
- AGIO United States
- HE United States
- Employees
- AGIO N/A
- HE N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- HE Electric Utilities: Central
- Sector
- AGIO Health Care
- HE Utilities
- Exchange
- AGIO Nasdaq
- HE Nasdaq
- Market Cap
- AGIO 2.4B
- HE 1.9B
- IPO Year
- AGIO 2013
- HE N/A
- Fundamental
- Price
- AGIO $40.72
- HE $11.29
- Analyst Decision
- AGIO Strong Buy
- HE Hold
- Analyst Count
- AGIO 5
- HE 4
- Target Price
- AGIO $57.25
- HE $10.94
- AVG Volume (30 Days)
- AGIO 577.5K
- HE 1.6M
- Earning Date
- AGIO 10-30-2025
- HE 11-07-2025
- Dividend Yield
- AGIO N/A
- HE N/A
- EPS Growth
- AGIO N/A
- HE N/A
- EPS
- AGIO 11.13
- HE N/A
- Revenue
- AGIO $40,875,000.00
- HE $3,122,881,000.00
- Revenue This Year
- AGIO $23.76
- HE $12.58
- Revenue Next Year
- AGIO $148.23
- HE $2.10
- P/E Ratio
- AGIO $3.67
- HE N/A
- Revenue Growth
- AGIO 30.57
- HE 2.36
- 52 Week Low
- AGIO $23.42
- HE $8.14
- 52 Week High
- AGIO $62.58
- HE $13.41
- Technical
- Relative Strength Index (RSI)
- AGIO 63.66
- HE 43.81
- Support Level
- AGIO $39.32
- HE $10.92
- Resistance Level
- AGIO $41.42
- HE $11.26
- Average True Range (ATR)
- AGIO 1.34
- HE 0.22
- MACD
- AGIO 0.34
- HE -0.06
- Stochastic Oscillator
- AGIO 87.58
- HE 28.06
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About HE Hawaiian Electric Industries Inc.
Hawaiian Electric Industries is the parent company of three Hawaii-based regulated utilities and owns a 10% minority interest in Hawaii's American Savings Bank. The utilities provide electricity on the five islands of Oahu, Hawaii, Maui, Molokai, and Lanai.